A novel allosteric site employs a conserved inhibition mechanism in human kidney‐type glutaminase

Glutaminase catalyses the metabolic process called glutaminolysis. Cancer cells harness glutaminolysis to increase energy reserves under stressful conditions for rapid proliferation. Glutaminases are upregulated in many tumours. In humans, the kidney‐type glutaminase (KGA) isoform is highly expressed in the kidney, brain, intestine, foetal liver, lymphocytes and in many tumours. Glutaminase inhibition is shown to be effective in controlling cancers. Previously, we and others reported the inhibition mechanism of KGA using various inhibitors that target the active and allosteric sites of the enzyme. Here, we report the identification of a novel allosteric site in KGA using the compound DDP through its complex crystal structure combined with mutational and hydrogen‐deuterium exchange mass spectrometry studies. This allosteric site is located at the dimer interface, situated ~ 31 Å away from the previously identified allosteric site and ~ 32 Å away from the active site. Remarkably, the mechanism of inhibition is conserved, irrespective of which allosteric pocket is targeted, causing the same conformational changes in the key loop near the active site (Glu312‐Pro329) and subsequent enzyme inactivation. Contrary to the previously identified allosteric site, the identified new allosteric site is primarily hydrophilic. This site could be effectively targeted for the synthesis of specific and potent water‐soluble inhibitors of glutaminase, which will lead to the development of anticancer drugs.

[1]  Jie Zheng,et al.  Recommendations for performing, interpreting and reporting hydrogen deuterium exchange mass spectrometry (HDX-MS) experiments , 2019, Nature Methods.

[2]  G. Mælandsmo,et al.  Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer , 2019, Breast Cancer Research.

[3]  Mary A Davis,et al.  Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice , 2019, International journal of radiation biology.

[4]  G. Anand,et al.  HDX‐MS reveals orthosteric and allosteric changes in apolipoprotein‐D structural dynamics upon binding of progesterone , 2018, Protein science : a publication of the Protein Society.

[5]  K. Lemberg,et al.  We're Not “DON” Yet: Optimal Dosing and Prodrug Delivery of 6-Diazo-5-oxo-L-norleucine , 2018, Molecular Cancer Therapeutics.

[6]  T. Tsukamoto,et al.  Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase. , 2018, Journal of medicinal chemistry.

[7]  William P. Katt,et al.  Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism , 2018, The Journal of Biological Chemistry.

[8]  P. Bhattacharya,et al.  Metabolic Differences in Glutamine Utilization Lead to Metabolic Vulnerabilities in Prostate Cancer , 2017, Scientific Reports.

[9]  H. Feng,et al.  The emerging role and targetability of the TCA cycle in cancer metabolism , 2017, Protein & Cell.

[10]  G. Anand,et al.  Channeling of cAMP in PDE-PKA Complexes Promotes Signal Adaptation. , 2017, Biophysical journal.

[11]  W. Yue,et al.  The origin and evolution of human glutaminases and their atypical C-terminal ankyrin repeats , 2017, The Journal of Biological Chemistry.

[12]  C. Thompson,et al.  Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine , 2017, The EMBO journal.

[13]  J. Locasale,et al.  Glutamine Metabolism in Cancer: Understanding the Heterogeneity. , 2017, Trends in cancer.

[14]  William P. Katt,et al.  A tale of two glutaminases: homologous enzymes with distinct roles in tumorigenesis. , 2017, Future medicinal chemistry.

[15]  Caifeng Xie,et al.  A novel glutaminase inhibitor-968 inhibits the migration and proliferation of non-small cell lung cancer cells by targeting EGFR/ERK signaling pathway , 2016, Oncotarget.

[16]  Junhua Wu,et al.  The Glutaminase-1 Inhibitor 968 Enhances Dihydroartemisinin-Mediated Antitumor Efficacy in Hepatocellular Carcinoma Cells , 2016, PloS one.

[17]  C. Dang,et al.  From Krebs to clinic: glutamine metabolism to cancer therapy , 2016, Nature Reviews Cancer.

[18]  B. C. Low,et al.  Structural basis for exploring the allosteric inhibition of human kidney type glutaminase , 2016, Oncotarget.

[19]  J. Locasale,et al.  The Warburg Effect: How Does it Benefit Cancer Cells? , 2016, Trends in biochemical sciences.

[20]  Chunxiao Zhou,et al.  Glutamine promotes ovarian cancer cell proliferation through the mTOR/S6 pathway , 2015, Endocrine-related cancer.

[21]  R. Deberardinis,et al.  Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cells , 2014, Proceedings of the National Academy of Sciences.

[22]  K. Thangavelu,et al.  Structural Basis for the Active Site Inhibition Mechanism of Human Kidney-Type Glutaminase (KGA) , 2014, Scientific Reports.

[23]  K. Thangavelu,et al.  Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism , 2012, Proceedings of the National Academy of Sciences.

[24]  William P. Katt,et al.  Dibenzophenanthridines as Inhibitors of Glutaminase C and Cancer Cell Proliferation , 2012, Molecular Cancer Therapeutics.

[25]  S. Berkowitz,et al.  The utility of hydrogen/deuterium exchange mass spectrometry in biopharmaceutical comparability studies. , 2011, Journal of pharmaceutical sciences.

[26]  C. Dang,et al.  Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. , 2010, Cancer cell.

[27]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[28]  John R Engen,et al.  High-speed and high-resolution UPLC separation at zero degrees Celsius. , 2008, Analytical chemistry.

[29]  Randy J. Read,et al.  Dauter Iterative model building , structure refinement and density modification with the PHENIX AutoBuild wizard , 2007 .

[30]  M. Tsai,et al.  Ankyrin repeat: a unique motif mediating protein-protein interactions. , 2006, Biochemistry.

[31]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[32]  Daniel C. Desrosiers,et al.  The ankyrin repeat as molecular architecture for protein recognition , 2004, Protein science : a publication of the Protein Society.

[33]  K. Resing,et al.  Protein analysis by hydrogen exchange mass spectrometry. , 2003, Annual review of biophysics and biomolecular structure.

[34]  S. Smerdon,et al.  The ankyrin repeat: a diversity of interactions on a common structural framework. , 1999, Trends in biochemical sciences.

[35]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[36]  S. Hartman,et al.  Glutaminase A of escherichia coli. Reactions with the substrate analogue, 6-diazo-5-oxonorleucine. , 1973, The Journal of biological chemistry.

[37]  Chunxiao Zhou,et al.  Glutaminase inhibitor compound 968 inhibits cell proliferation and sensitizes paclitaxel in ovarian cancer. , 2016, American journal of translational research.

[38]  Taofeek K Owonikoko,et al.  Altered glutamine metabolism and therapeutic opportunities for lung cancer. , 2014, Clinical lung cancer.

[39]  Z. Otwinowski,et al.  Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.